Stockreport

ImmunityBio Says Potential Lymphoma Therapy Extends Complete Response to 15 Months [Yahoo! Finance]

ImmunityBio, Inc.  (IBRX) 
PDF ImmunityBio (IBRX) said Friday the latest efficacy and safety results from an ongoing clinical trial [Read more]